Supernus Pharmaceuticals (NASDAQ:SUPN) Releases Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Key Points

• Reported earnings missed expectations: Supernus posted EPS of $0.35 versus the $0.49 consensus and revenue of $208.6 million versus $217.56 million expected, despite revenue increasing 18% year over year.
• Management raised 2026 guidance: The company now expects standalone revenue of $875 million–$900 million and non-GAAP operating earnings of $160 million–$180 million, citing strong momentum in Qelbree, ZURZUVAE, ONAPGO, and GOCOVRI.
• Merger and pipeline progress provide catalysts: Shareholders approved the Indivior merger, expected to close November 2, with $125 million in anticipated annual cost synergies; several Phase II programs also remain in development, though some trial timelines have slowed.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) announced its quarterly earnings results on Thursday. The specialty pharmaceutical company reported $0.35 EPS for the quarter, missing analysts' consensus estimates of $0.49 by ($0.14), FiscalAI reports. The business had revenue of $208.60 million for the quarter, compared to analysts' expectations of $217.56 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The business's quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.80) earnings per share.

Here are the key takeaways from Supernus Pharmaceuticals' conference call:

• Strong third-quarter performance: Revenue rose 18% year over year to a record $226.8 million, while GAAP net income reached $20.9 million versus a $45.1 million loss in the prior-year quarter.
• Management raised standalone 2026 guidance, now expecting total revenue of $875 million–$900 million and non-GAAP operating earnings of $160 million–$180 million.
• Growth products continued to gain momentum, with combined revenue from Qelbree, ZURZUVAE, ONAPGO, and GOCOVRI up 43%; Qelbree prescriptions increased 18%, ZURZUVAE U.S. sales grew about 53%, and ONAPGO sales rose 27% sequentially.
• Supernus and Indivior shareholders approved the merger, with closing expected November 2. Management remains confident in achieving the projected $125 million in annual cost synergies and plans to issue combined 2027 guidance in February.
• SPN-820 and SPN-817 Phase IIb trials continue enrolling, while SPN-443 is expected to enter Phase I by year-end; SPN-817 epilepsy data may not be available until 2028 because recruitment is progressing slowly.

Supernus Pharmaceuticals Stock Up 1.9%

Supernus Pharmaceuticals stock traded up $0.76 during trading hours on Thursday, hitting $41.84. The stock had a trading volume of 1,885,191 shares, compared to its average volume of 976,567. The stock has a market capitalization of $2.44 billion, a P/E ratio of -21.79, a price-to-earnings-growth ratio of 1.21 and a beta of 0.55. Supernus Pharmaceuticals has a 12-month low of $37.54 and a 12-month high of $59.68. The stock's 50-day moving average price is $42.61 and its 200-day moving average price is $47.37.

Analyst Ratings Changes

Several brokerages have recently weighed in on SUPN. Wall Street Zen cut Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Cantor Fitzgerald raised their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an "overweight" rating in a research note on Thursday, July 9th. Zacks Research downgraded Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Monday, October 5th. Finally, Weiss Ratings reiterated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research report on Monday, September 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Supernus Pharmaceuticals has a consensus rating of "Reduce" and an average target price of $62.33.

Supernus Pharmaceuticals News Roundup

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Adjusted earnings beat expectations: Supernus reported third-quarter adjusted earnings of $0.93 per share, well above the Zacks consensus estimate of $0.49. Although earnings declined from $1.01 a year earlier, the sizable estimate beat supports investor confidence in the company’s operating performance. Supernus Pharmaceuticals Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: Sales growth and guidance were encouraging: Third-quarter revenue rose 18% year over year to $208.6 million, while management reportedly provided optimistic full-year sales guidance. Continued commercial momentum is a positive signal for future revenue and cash generation. Supernus Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Pipeline progress added a potential catalyst: Supernus advanced its Phase 2 SPN-821 depression study. Further clinical progress could expand the company’s growth opportunities beyond its existing CNS portfolio, though development and regulatory risks remain. Supernus Advances SPN-821 Depression Trial
• Neutral Sentiment: Reported earnings figures vary by measure: One report cited $0.35 in EPS versus a $0.49 consensus estimate, while the adjusted figure reported by Zacks was $0.93. Investors should verify the reconciliation between GAAP and adjusted results when assessing the quarter. Supernus Q3 2026 Earnings Call Transcript
• Negative Sentiment: Profitability remains a concern: The reported quarter included a negative net margin, and some published results showed EPS and revenue below consensus. These factors could limit the durability of the positive reaction if future results do not sustain the adjusted-earnings beat.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company's activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus' marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.